Long-term clinical efficacy and a possible mechanism of action of different modes of pneumococcal vaccination in asthma patients
Протасов А. Д., Жестков А. В., Костинов М. П., Корyмасов Е. А., Штеyнер М. Л., Тезиков Y. В., Липатов И. С., Решетникова В. П., Лаврент'Ьева Н. Е.
Пульмонология
Т. 28, Вып. 2, С. 193-199
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.18093/0869-0189-2018-28-2-193-199
Аннотация:
The aim of this study was to assess long-term effects of pneumococcal vaccination with 23-valent polysaccharide vaccine (PPV23) and 13-valent conjugate vaccine (PCV13) in patients with bronchial asthma. Methods. One hundred and three patients with mild to severe asthma were involved. They were randomly assigned to vaccination with PCV13, or PPV23, or PPV23 followed by PCV13, or vice versa. Clinical efficacy of vaccination was evaluated using number of asthma exacerbation a year before and 1 and 4 years after the vaccination; need in antibiotics a year before and 1 and 4 years after the vaccination; and number of hospitalizations due to asthma exacerbation a year before and 1 and 4 years after the vaccination. Results. In a year after vaccination, number of patients who had not experienced asthma exacerbation increased significantly in PPV23, PPV23/PCV13, and PCV13/PPV23 groups (p < 0.01 to p < 0.001). In 4 years after vaccination, number of patients without exacerbations increased sign
Ключевые слова:
Bronchial asthma; Clinical efficacy; Conjugate pneumococcal vaccine; Long-term effects; Mechanism of action; Polysaccharide pneumococcal vaccine; Vaccination
antibiotic agent; Pneumococcus vaccine; Article; asthma; controlled study; disease exacerbation; drug efficacy; drug mechanism; hospitalization; human; immunopathogenesis; major clinical study; randomized controlled trial; vaccination
Язык текста: Русский
ISSN: 0869-0189
Протасов А. Д.
Жестков А. В.
Костинов М. П. Михаил Петрович 1956-
Корyмасов Е. А.
Штеyнер М. Л.
Тезиков Y. В.
Липатов И. С.
Решетникова В. П.
Лаврент'Ьева Н. Е.
Protasov A. D.
Zhestkov A. V.
Kostinov M. P. Mikhail Petrovich 1956-
Korymasov E. A.
Shteyner M. L.
Tezikov Y. V.
Lipatov I. S.
Reshetnikova V. P.
Lavrent'Yeva N. E.
Long-term clinical efficacy and a possible mechanism of action of different modes of pneumococcal vaccination in asthma patients
Текст визуальный непосредственный
Пульмонология
Научно-практический журнал "Пульмонология"
Т. 28, Вып. 2 С. 193-199
2018
Статья
Bronchial asthma Clinical efficacy Conjugate pneumococcal vaccine Long-term effects Mechanism of action Polysaccharide pneumococcal vaccine Vaccination
antibiotic agent Pneumococcus vaccine Article asthma controlled study disease exacerbation drug efficacy drug mechanism hospitalization human immunopathogenesis major clinical study randomized controlled trial vaccination
The aim of this study was to assess long-term effects of pneumococcal vaccination with 23-valent polysaccharide vaccine (PPV23) and 13-valent conjugate vaccine (PCV13) in patients with bronchial asthma. Methods. One hundred and three patients with mild to severe asthma were involved. They were randomly assigned to vaccination with PCV13, or PPV23, or PPV23 followed by PCV13, or vice versa. Clinical efficacy of vaccination was evaluated using number of asthma exacerbation a year before and 1 and 4 years after the vaccination; need in antibiotics a year before and 1 and 4 years after the vaccination; and number of hospitalizations due to asthma exacerbation a year before and 1 and 4 years after the vaccination. Results. In a year after vaccination, number of patients who had not experienced asthma exacerbation increased significantly in PPV23, PPV23/PCV13, and PCV13/PPV23 groups (p < 0.01 to p < 0.001). In 4 years after vaccination, number of patients without exacerbations increased sign